BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 37861033)

  • 1. VEGF165b Mutant Promotes the Apoptosis of Murine Breast Cancer Cells Induced by Paclitaxel by Inducing Tumor Vessel Maturation.
    Liang C; Li Y; Guo E; Bai S; Wang Y; Zhang H
    Protein Pept Lett; 2023; 30(11):951-958. PubMed ID: 37861033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.
    Tonissi F; Lattanzio L; Merlano MC; Infante L; Lo Nigro C; Garrone O
    Invest New Drugs; 2015 Aug; 33(4):801-9. PubMed ID: 25947567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.
    Kim TJ; Landen CN; Lin YG; Mangala LS; Lu C; Nick AM; Stone RL; Merritt WM; Armaiz-Pena G; Jennings NB; Coleman RL; Tice DA; Sood AK
    Cancer Biol Ther; 2009 Dec; 8(23):2263-72. PubMed ID: 19829059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF165b and its mutant demonstrate immunomodulatory, not merely anti-angiogenic functions, in tumor-bearing mice.
    Zhang H; Xia W; Liang C; Wang X; Zhi L; Guo C; Niu Z; Zhu W
    Mol Immunol; 2020 Apr; 122():132-140. PubMed ID: 32353584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
    Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
    Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF165b mutant with a prolonged half-life and enhanced anti-tumor potency in a mouse model.
    Zhang H; Jia E; Xia W; Lu C; Zhu W
    J Biotechnol; 2018 Oct; 284():84-90. PubMed ID: 30134149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.
    Cesca M; Morosi L; Berndt A; Fuso Nerini I; Frapolli R; Richter P; Decio A; Dirsch O; Micotti E; Giordano S; D'Incalci M; Davoli E; Zucchetti M; Giavazzi R
    Mol Cancer Ther; 2016 Jan; 15(1):125-35. PubMed ID: 26494857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF
    Boudria A; Abou Faycal C; Jia T; Gout S; Keramidas M; Didier C; Lemaître N; Manet S; Coll JL; Toffart AC; Moro-Sibilot D; Albiges-Rizo C; Josserand V; Faurobert E; Brambilla C; Brambilla E; Gazzeri S; Eymin B
    Oncogene; 2019 Feb; 38(7):1050-1066. PubMed ID: 30194450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
    Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
    J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.
    Volk LD; Flister MJ; Bivens CM; Stutzman A; Desai N; Trieu V; Ran S
    Neoplasia; 2008 Jun; 10(6):613-23. PubMed ID: 18516298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways
    Zhang X; Zhang Y; Jia Y; Qin T; Zhang C; Li Y; Huang C; Liu Z; Wang J; Li K
    Cancer Biol Med; 2020 May; 17(2):418-432. PubMed ID: 32587778
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications.
    Liu J; Zhang X; Li G; Xu F; Li S; Teng L; Li Y; Sun F
    Int J Nanomedicine; 2019; 14():8819-8834. PubMed ID: 31819410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
    Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of radiation response with bevacizumab.
    Hoang T; Huang S; Armstrong E; Eickhoff JC; Harari PM
    J Exp Clin Cancer Res; 2012 Apr; 31(1):37. PubMed ID: 22538017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells.
    Atmaca H; Uzunoglu S
    Eur Cytokine Netw; 2014 Mar; 25(1):1-7. PubMed ID: 24941346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model
    Wang M; Zeng Q; Li Y; Imani S; Xie D; Li Y; Han Y; Fan J
    J Drug Target; 2020 Nov; 28(9):961-969. PubMed ID: 32374627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.
    Mollard S; Ciccolini J; Imbs DC; El Cheikh R; Barbolosi D; Benzekry S
    Oncotarget; 2017 Apr; 8(14):23087-23098. PubMed ID: 28416742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
    Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
    Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
    Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
    Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
    Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.